Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus LAMPIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus LAMPIT.
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE vs LAMPIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a mitochondrial electron transport inhibitor that selectively targets the cytochrome bc1 complex, disrupting pyrimidine synthesis in Plasmodium. Proguanil hydrochloride is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. The combination synergistically inhibits plasmodial replication.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
250 mg atovaquone/100 mg proguanil hydrochloride (1 tablet) orally once daily for prophylaxis; 4 tablets (1000 mg/400 mg) orally once daily for 3 consecutive days for treatment.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
None Documented
None Documented
Atovaquone: terminal half-life 2-3 days (67-83 hours); prolonged to 4-5 days in malaria due to drug accumulation. Proguanil: terminal half-life 12-21 hours; cycloguanil 14-21 hours.
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Atovaquone: >94% excreted unchanged in feces via biliary elimination; renal excretion minimal (<1%). Proguanil: ~40-60% excreted renally as unchanged drug and metabolites (primarily cycloguanil and 4-chlorophenylbiguanide).
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Category A/B
Category C
Antiprotozoal
Antiprotozoal